Path to Product Inclusion in Clinical Guidelines is Disclosed in New Research Report by FirstWord15 Mar 2013 • by Natalie Aster
As evidence-based medicine continues its march up healthcare agendas round the globe, pharma companies are being more closely monitored than ever before. In an evidence-based world, it is raw clinical data—untainted in its gathering by financial gain or academic prestige—that counts.
The report “The Path to Product Inclusion in Clinical Guidelines: Strategies for Success” by FirstWord informs the clinical guidelines that go some way to determining how medicine is practised and increasingly inform formulary and reimbursement decisions as well as continuing medical education (CME) materials used by physicians.
The Path to Product Inclusion in Clinical Guidelines: Strategies for Success
Published: February, 2013
Price: US$ 495.00
An evidence-based world makes it all the more crucial for pharma companies to influence the interpretation of clinical trial results and, at the same time, makes it harder for them to do so. Few companies will speak, even off the record, on the subject. Those that will, claim that the only way to get noticed in an evidence-based world is via a sophisticated publication strategy that can present data with the credibility as well as the visibility in the best journals.
This report looks at how clinical guidelines are developed, how they are used in practice and how this is changing. In many ways it sets the stage for an interesting battle, between proponents of guidelines that focus on the patient and those who have the payer more in mind. In this battle, the degree of implementation of the guidelines will become more closely observed.
Currently, the situation has been described as“a practice famine amid an evidence glut” as doctors find the guidelines often don’t apply to the patient in front of them who may be taking several other medications.
The increasingly hefty presence of the payer also impacts on a central conundrum for pharma, which is how companies can generate the real-world data that payers want when the drug has not been used. And how can a drug be used if it doesn’t have the authority required in an evidence-based world? For these and other reasons people are asking just how holy is the holy grail of evidence-based medicine?
Within that, they are reflecting on what evidence counts most and what is required for doctors to actually use the guidelines?
More information can be found in the report “The Path to Product Inclusion in Clinical Guidelines: Strategies for Success” by FirstWord.
To order the report or ask for sample pages contact email@example.com